Bio-Thera Solutions, Ltd. (SHA:688177)
21.03
+0.82 (4.06%)
At close: Sep 30, 2026
Bio-Thera Solutions Revenue
Bio-Thera Solutions had revenue of 266.96M CNY in the quarter ending June 30, 2026, with 13.44% growth. This brings the company's revenue in the last twelve months to 1.01B, up 29.27% year-over-year. In the year 2025, Bio-Thera Solutions had annual revenue of 935.22M with 25.84% growth.
Revenue (ttm)
1.01B
Revenue Growth
+29.27%
P/S Ratio
8.61
Revenue / Employee
687.88K
Employees
1,471
Market Cap
8.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 935.22M | 192.05M | 25.84% |
| Dec 31, 2024 | 743.17M | 38.37M | 5.44% |
| Dec 31, 2023 | 704.79M | 249.66M | 54.86% |
| Dec 31, 2022 | 455.13M | -381.45M | -45.60% |
| Dec 31, 2021 | 836.58M | 653.72M | 357.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Novogene | 2.28B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 2.03B |
| Aurisco Pharmaceutical | 1.70B |
| Vcanbio Cell & Gene Engineering Corp., | 1.40B |
| Liaoning Chengda Biotechnology | 1.36B |
| Chengdu Easton Biopharmaceuticals | 1.34B |
| Daan Gene | 746.91M |